Article Text

other Versions

PDF
Treatment with immunosuppressive therapy in patients with pars planitis: experience of a reference centre in Mexico
  1. Juan Carlos Serna-Ojeda,
  2. Miguel Pedroza-Seres
  1. Department of Uveitis and Ocular Immunology, Instituto de Oftalmologia “Conde de Valenciana”, Mexico City, Mexico
  1. Correspondence to Dr Miguel Pedroza-Seres, Department of Uveitis and Ocular Immunology, Instituto de Oftalmologia “Conde de Valenciana”, Chimalpopoca 14, Mexico City 06800, Mexico; mpedrozaseres{at}gmail.com

Abstract

Aim To evaluate the clinical course of the patients with pars planitis that received immunosuppressive drugs.

Methods We retrospectively analysed the data of 10 years from 374 patients with pars planitis in a large reference centre in Mexico City and included 49 patients (92 eyes).

Results Median age at presentation was 8 years. 35 patients (71.4%) were male and 43 patients (87.7%) had bilateral disease. Diverse immunosuppressive medications were used, mainly methotrexate (69.4%) and azathioprine (63.3%) with 18 patients requiring more than one drug. The main indications for starting immunosuppressive therapy were lack of response to initial treatment and advance disease at presentation. The results showed good response with steroid reduction (69.3% of patients), visual acuity improvement (51% of patients) and inflammatory disease reduction (59.1% of patients). In 25 patients (51%), steroids were started previous to immunosuppressors and in 24 (49%) at the same time without significant difference in clinical improvement (p=0.210) or visual outcome (p=0.498). Thirteen patients (26.5%) presented mild adverse effects. The median of the final visual acuity was 20/40. The median follow-up time was 44 months (range 13–115 months).

Conclusions Immunosuppressive therapy allows an adequate control of inflammatory disease in pars planitis, with clinical and visual improvement and steroid dose reduction.

  • Inflammation
  • Drugs

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.